Association between Expression of Transcription Factor Sp1 and Increased Vascular Endothelial Growth Factor Expression, Advanced Stage, and Poor Survival in Patients with Resected Gastric Cancer
The biological and clinical behaviors of cancer are affected by multiple molecular pathways that are under the control of transcription factors. Improved understanding of how transcription factors affect cancer biology may lead to improved ability to predict clinical outcome and discovery of novel t...
Gespeichert in:
| Veröffentlicht in: | Clinical cancer research 2004-06, Vol.10 (12), p.4109-4117 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 4117 |
|---|---|
| container_issue | 12 |
| container_start_page | 4109 |
| container_title | Clinical cancer research |
| container_volume | 10 |
| creator | Yao, James C Wang, Liwei Wei, Daoyan Gong, Weida Hassan, Manal Wu, Tsung-Teh Mansfield, Paul Ajani, Jaffer Xie, Keping |
| description | The biological and clinical behaviors of cancer are affected by multiple molecular pathways that are under the control of
transcription factors. Improved understanding of how transcription factors affect cancer biology may lead to improved ability
to predict clinical outcome and discovery of novel therapeutic strategies. We evaluated the relationship between Sp1 and vascular
endothelial growth factor (VEGF) expression, as well as their effect on survival in 86 cases of resected human gastric cancer.
The degree of VEGF expression correlated highly with Sp1 expression ( P < 0.01). Patients with high Sp1 expression were 98 times more likely to have high VEGF expression compared with those with
negative Sp1 expression. Clinically, negative or weak Sp1 expression was associated with early stage (IA) in gastric cancer.
Strong Sp1 expression was more frequently observed among patients with stage IB–IV disease ( P = 0.035). Similarly, whereas strong Sp1 expression was uncommonly observed among patients with N0 or N1 disease (19 and 16%),
N2/N3 gastric cancer was associated with strong Sp1 expression (48%; P = 0.034). Strong Sp1 expression was also associated with inferior survival. The median survival duration in patients who
had a tumor with a negative, weak, and strong Sp1 expression was 44, 38, and 8 months ( P = 0.0075), respectively, whereas patients with strong VEGF expression had a shorter survival duration; the difference was
not statistically significant. When Sp1 and VEGF expression, stage, completeness of resection, histology, and patient age
were entered in a Cox proportional hazards model, strong Sp1 expression ( P = 0.021) and an advanced disease stage ( P < 0.001) were independently prognostic of poor survival. Given the importance of Sp1 in the expression of VEGF, our data
suggest that dysregulated Sp1 expression and activation play important roles in VEGF overexpression and, thus, gastric cancer
development and progression. |
| doi_str_mv | 10.1158/1078-0432.CCR-03-0628 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_66652062</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>66652062</sourcerecordid><originalsourceid>FETCH-LOGICAL-c369t-74a4601bf5b33c0c541765c2e9d0e9c8bca3f9d4cb3ec928b77893542b155ff93</originalsourceid><addsrcrecordid>eNpNkl1v0zAUhiMEYh_wE0C-AQlpGXYcO8llFXVl0iSmbXBrOScni1EaF9tp4e_tl-G0ncaVLet5X1vncZJ8YPSSMVF-ZbQoU5rz7LKu71LKUyqz8lVyyoQoUp5J8Trun5mT5Mz7X5SynNH8bXLCRMaKKi9Ok6eF9xaMDsaOpMGwQxzJ8s_Goffzke3Ig9OjB2c2e-ZKQ7CO3G8Y0WNLrkdwqD225Kf2MA3akeXY2tDjYPRAVs7uQv8ceum9IIt2q0eIufugH_FiX3Zr5-bJbc02Zs1IbuO7cAye7ExsuUOPEGJkpX1wBkg9N7h3yZtODx7fH9fz5MfV8qH-lt58X13Xi5sUuKxCWuQ6l5Q1nWg4BwoiZ4UUkGHVUqygbEDzrmpzaDhClZVNUZQVF3nWxJF2XcXPk8-H3o2zvyf0Qa2NBxwGPaKdvJJSiixaiKA4gOCs9w47tXFmrd1fxaia5alZjJrFqChPUa5meTH38XjB1KyxfUkdbUXg0xGIs9ZDF8WA8f9xFRWSysh9OXC9eex3xqGC_aTi8FE76PfvyFT8DBX_B8jhtEA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>66652062</pqid></control><display><type>article</type><title>Association between Expression of Transcription Factor Sp1 and Increased Vascular Endothelial Growth Factor Expression, Advanced Stage, and Poor Survival in Patients with Resected Gastric Cancer</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>American Association for Cancer Research</source><source>Alma/SFX Local Collection</source><creator>Yao, James C ; Wang, Liwei ; Wei, Daoyan ; Gong, Weida ; Hassan, Manal ; Wu, Tsung-Teh ; Mansfield, Paul ; Ajani, Jaffer ; Xie, Keping</creator><creatorcontrib>Yao, James C ; Wang, Liwei ; Wei, Daoyan ; Gong, Weida ; Hassan, Manal ; Wu, Tsung-Teh ; Mansfield, Paul ; Ajani, Jaffer ; Xie, Keping</creatorcontrib><description>The biological and clinical behaviors of cancer are affected by multiple molecular pathways that are under the control of
transcription factors. Improved understanding of how transcription factors affect cancer biology may lead to improved ability
to predict clinical outcome and discovery of novel therapeutic strategies. We evaluated the relationship between Sp1 and vascular
endothelial growth factor (VEGF) expression, as well as their effect on survival in 86 cases of resected human gastric cancer.
The degree of VEGF expression correlated highly with Sp1 expression ( P < 0.01). Patients with high Sp1 expression were 98 times more likely to have high VEGF expression compared with those with
negative Sp1 expression. Clinically, negative or weak Sp1 expression was associated with early stage (IA) in gastric cancer.
Strong Sp1 expression was more frequently observed among patients with stage IB–IV disease ( P = 0.035). Similarly, whereas strong Sp1 expression was uncommonly observed among patients with N0 or N1 disease (19 and 16%),
N2/N3 gastric cancer was associated with strong Sp1 expression (48%; P = 0.034). Strong Sp1 expression was also associated with inferior survival. The median survival duration in patients who
had a tumor with a negative, weak, and strong Sp1 expression was 44, 38, and 8 months ( P = 0.0075), respectively, whereas patients with strong VEGF expression had a shorter survival duration; the difference was
not statistically significant. When Sp1 and VEGF expression, stage, completeness of resection, histology, and patient age
were entered in a Cox proportional hazards model, strong Sp1 expression ( P = 0.021) and an advanced disease stage ( P < 0.001) were independently prognostic of poor survival. Given the importance of Sp1 in the expression of VEGF, our data
suggest that dysregulated Sp1 expression and activation play important roles in VEGF overexpression and, thus, gastric cancer
development and progression.</description><identifier>ISSN: 1078-0432</identifier><identifier>EISSN: 1557-3265</identifier><identifier>DOI: 10.1158/1078-0432.CCR-03-0628</identifier><identifier>PMID: 15217947</identifier><language>eng</language><publisher>Philadelphia, PA: American Association for Cancer Research</publisher><subject>Aged ; Antineoplastic agents ; Biological and medical sciences ; Blotting, Western ; Disease Progression ; Female ; Humans ; Immunohistochemistry ; Lymphatic Metastasis ; Male ; Medical sciences ; Middle Aged ; Multivariate Analysis ; Odds Ratio ; Pharmacology. Drug treatments ; Sp1 Transcription Factor - biosynthesis ; Stomach - metabolism ; Stomach Neoplasms - metabolism ; Stomach Neoplasms - mortality ; Time Factors ; Treatment Outcome ; Tumor Cells, Cultured ; Tumors ; Vascular Endothelial Growth Factor A - biosynthesis</subject><ispartof>Clinical cancer research, 2004-06, Vol.10 (12), p.4109-4117</ispartof><rights>2004 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c369t-74a4601bf5b33c0c541765c2e9d0e9c8bca3f9d4cb3ec928b77893542b155ff93</citedby><cites>FETCH-LOGICAL-c369t-74a4601bf5b33c0c541765c2e9d0e9c8bca3f9d4cb3ec928b77893542b155ff93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,3357,27929,27930</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15905606$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15217947$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yao, James C</creatorcontrib><creatorcontrib>Wang, Liwei</creatorcontrib><creatorcontrib>Wei, Daoyan</creatorcontrib><creatorcontrib>Gong, Weida</creatorcontrib><creatorcontrib>Hassan, Manal</creatorcontrib><creatorcontrib>Wu, Tsung-Teh</creatorcontrib><creatorcontrib>Mansfield, Paul</creatorcontrib><creatorcontrib>Ajani, Jaffer</creatorcontrib><creatorcontrib>Xie, Keping</creatorcontrib><title>Association between Expression of Transcription Factor Sp1 and Increased Vascular Endothelial Growth Factor Expression, Advanced Stage, and Poor Survival in Patients with Resected Gastric Cancer</title><title>Clinical cancer research</title><addtitle>Clin Cancer Res</addtitle><description>The biological and clinical behaviors of cancer are affected by multiple molecular pathways that are under the control of
transcription factors. Improved understanding of how transcription factors affect cancer biology may lead to improved ability
to predict clinical outcome and discovery of novel therapeutic strategies. We evaluated the relationship between Sp1 and vascular
endothelial growth factor (VEGF) expression, as well as their effect on survival in 86 cases of resected human gastric cancer.
The degree of VEGF expression correlated highly with Sp1 expression ( P < 0.01). Patients with high Sp1 expression were 98 times more likely to have high VEGF expression compared with those with
negative Sp1 expression. Clinically, negative or weak Sp1 expression was associated with early stage (IA) in gastric cancer.
Strong Sp1 expression was more frequently observed among patients with stage IB–IV disease ( P = 0.035). Similarly, whereas strong Sp1 expression was uncommonly observed among patients with N0 or N1 disease (19 and 16%),
N2/N3 gastric cancer was associated with strong Sp1 expression (48%; P = 0.034). Strong Sp1 expression was also associated with inferior survival. The median survival duration in patients who
had a tumor with a negative, weak, and strong Sp1 expression was 44, 38, and 8 months ( P = 0.0075), respectively, whereas patients with strong VEGF expression had a shorter survival duration; the difference was
not statistically significant. When Sp1 and VEGF expression, stage, completeness of resection, histology, and patient age
were entered in a Cox proportional hazards model, strong Sp1 expression ( P = 0.021) and an advanced disease stage ( P < 0.001) were independently prognostic of poor survival. Given the importance of Sp1 in the expression of VEGF, our data
suggest that dysregulated Sp1 expression and activation play important roles in VEGF overexpression and, thus, gastric cancer
development and progression.</description><subject>Aged</subject><subject>Antineoplastic agents</subject><subject>Biological and medical sciences</subject><subject>Blotting, Western</subject><subject>Disease Progression</subject><subject>Female</subject><subject>Humans</subject><subject>Immunohistochemistry</subject><subject>Lymphatic Metastasis</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Multivariate Analysis</subject><subject>Odds Ratio</subject><subject>Pharmacology. Drug treatments</subject><subject>Sp1 Transcription Factor - biosynthesis</subject><subject>Stomach - metabolism</subject><subject>Stomach Neoplasms - metabolism</subject><subject>Stomach Neoplasms - mortality</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><subject>Tumor Cells, Cultured</subject><subject>Tumors</subject><subject>Vascular Endothelial Growth Factor A - biosynthesis</subject><issn>1078-0432</issn><issn>1557-3265</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpNkl1v0zAUhiMEYh_wE0C-AQlpGXYcO8llFXVl0iSmbXBrOScni1EaF9tp4e_tl-G0ncaVLet5X1vncZJ8YPSSMVF-ZbQoU5rz7LKu71LKUyqz8lVyyoQoUp5J8Trun5mT5Mz7X5SynNH8bXLCRMaKKi9Ok6eF9xaMDsaOpMGwQxzJ8s_Goffzke3Ig9OjB2c2e-ZKQ7CO3G8Y0WNLrkdwqD225Kf2MA3akeXY2tDjYPRAVs7uQv8ceum9IIt2q0eIufugH_FiX3Zr5-bJbc02Zs1IbuO7cAye7ExsuUOPEGJkpX1wBkg9N7h3yZtODx7fH9fz5MfV8qH-lt58X13Xi5sUuKxCWuQ6l5Q1nWg4BwoiZ4UUkGHVUqygbEDzrmpzaDhClZVNUZQVF3nWxJF2XcXPk8-H3o2zvyf0Qa2NBxwGPaKdvJJSiixaiKA4gOCs9w47tXFmrd1fxaia5alZjJrFqChPUa5meTH38XjB1KyxfUkdbUXg0xGIs9ZDF8WA8f9xFRWSysh9OXC9eex3xqGC_aTi8FE76PfvyFT8DBX_B8jhtEA</recordid><startdate>20040615</startdate><enddate>20040615</enddate><creator>Yao, James C</creator><creator>Wang, Liwei</creator><creator>Wei, Daoyan</creator><creator>Gong, Weida</creator><creator>Hassan, Manal</creator><creator>Wu, Tsung-Teh</creator><creator>Mansfield, Paul</creator><creator>Ajani, Jaffer</creator><creator>Xie, Keping</creator><general>American Association for Cancer Research</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20040615</creationdate><title>Association between Expression of Transcription Factor Sp1 and Increased Vascular Endothelial Growth Factor Expression, Advanced Stage, and Poor Survival in Patients with Resected Gastric Cancer</title><author>Yao, James C ; Wang, Liwei ; Wei, Daoyan ; Gong, Weida ; Hassan, Manal ; Wu, Tsung-Teh ; Mansfield, Paul ; Ajani, Jaffer ; Xie, Keping</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c369t-74a4601bf5b33c0c541765c2e9d0e9c8bca3f9d4cb3ec928b77893542b155ff93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Aged</topic><topic>Antineoplastic agents</topic><topic>Biological and medical sciences</topic><topic>Blotting, Western</topic><topic>Disease Progression</topic><topic>Female</topic><topic>Humans</topic><topic>Immunohistochemistry</topic><topic>Lymphatic Metastasis</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Multivariate Analysis</topic><topic>Odds Ratio</topic><topic>Pharmacology. Drug treatments</topic><topic>Sp1 Transcription Factor - biosynthesis</topic><topic>Stomach - metabolism</topic><topic>Stomach Neoplasms - metabolism</topic><topic>Stomach Neoplasms - mortality</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><topic>Tumor Cells, Cultured</topic><topic>Tumors</topic><topic>Vascular Endothelial Growth Factor A - biosynthesis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yao, James C</creatorcontrib><creatorcontrib>Wang, Liwei</creatorcontrib><creatorcontrib>Wei, Daoyan</creatorcontrib><creatorcontrib>Gong, Weida</creatorcontrib><creatorcontrib>Hassan, Manal</creatorcontrib><creatorcontrib>Wu, Tsung-Teh</creatorcontrib><creatorcontrib>Mansfield, Paul</creatorcontrib><creatorcontrib>Ajani, Jaffer</creatorcontrib><creatorcontrib>Xie, Keping</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical cancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yao, James C</au><au>Wang, Liwei</au><au>Wei, Daoyan</au><au>Gong, Weida</au><au>Hassan, Manal</au><au>Wu, Tsung-Teh</au><au>Mansfield, Paul</au><au>Ajani, Jaffer</au><au>Xie, Keping</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Association between Expression of Transcription Factor Sp1 and Increased Vascular Endothelial Growth Factor Expression, Advanced Stage, and Poor Survival in Patients with Resected Gastric Cancer</atitle><jtitle>Clinical cancer research</jtitle><addtitle>Clin Cancer Res</addtitle><date>2004-06-15</date><risdate>2004</risdate><volume>10</volume><issue>12</issue><spage>4109</spage><epage>4117</epage><pages>4109-4117</pages><issn>1078-0432</issn><eissn>1557-3265</eissn><abstract>The biological and clinical behaviors of cancer are affected by multiple molecular pathways that are under the control of
transcription factors. Improved understanding of how transcription factors affect cancer biology may lead to improved ability
to predict clinical outcome and discovery of novel therapeutic strategies. We evaluated the relationship between Sp1 and vascular
endothelial growth factor (VEGF) expression, as well as their effect on survival in 86 cases of resected human gastric cancer.
The degree of VEGF expression correlated highly with Sp1 expression ( P < 0.01). Patients with high Sp1 expression were 98 times more likely to have high VEGF expression compared with those with
negative Sp1 expression. Clinically, negative or weak Sp1 expression was associated with early stage (IA) in gastric cancer.
Strong Sp1 expression was more frequently observed among patients with stage IB–IV disease ( P = 0.035). Similarly, whereas strong Sp1 expression was uncommonly observed among patients with N0 or N1 disease (19 and 16%),
N2/N3 gastric cancer was associated with strong Sp1 expression (48%; P = 0.034). Strong Sp1 expression was also associated with inferior survival. The median survival duration in patients who
had a tumor with a negative, weak, and strong Sp1 expression was 44, 38, and 8 months ( P = 0.0075), respectively, whereas patients with strong VEGF expression had a shorter survival duration; the difference was
not statistically significant. When Sp1 and VEGF expression, stage, completeness of resection, histology, and patient age
were entered in a Cox proportional hazards model, strong Sp1 expression ( P = 0.021) and an advanced disease stage ( P < 0.001) were independently prognostic of poor survival. Given the importance of Sp1 in the expression of VEGF, our data
suggest that dysregulated Sp1 expression and activation play important roles in VEGF overexpression and, thus, gastric cancer
development and progression.</abstract><cop>Philadelphia, PA</cop><pub>American Association for Cancer Research</pub><pmid>15217947</pmid><doi>10.1158/1078-0432.CCR-03-0628</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1078-0432 |
| ispartof | Clinical cancer research, 2004-06, Vol.10 (12), p.4109-4117 |
| issn | 1078-0432 1557-3265 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_66652062 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; American Association for Cancer Research; Alma/SFX Local Collection |
| subjects | Aged Antineoplastic agents Biological and medical sciences Blotting, Western Disease Progression Female Humans Immunohistochemistry Lymphatic Metastasis Male Medical sciences Middle Aged Multivariate Analysis Odds Ratio Pharmacology. Drug treatments Sp1 Transcription Factor - biosynthesis Stomach - metabolism Stomach Neoplasms - metabolism Stomach Neoplasms - mortality Time Factors Treatment Outcome Tumor Cells, Cultured Tumors Vascular Endothelial Growth Factor A - biosynthesis |
| title | Association between Expression of Transcription Factor Sp1 and Increased Vascular Endothelial Growth Factor Expression, Advanced Stage, and Poor Survival in Patients with Resected Gastric Cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-15T04%3A36%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Association%20between%20Expression%20of%20Transcription%20Factor%20Sp1%20and%20Increased%20Vascular%20Endothelial%20Growth%20Factor%20Expression,%20Advanced%20Stage,%20and%20Poor%20Survival%20in%20Patients%20with%20Resected%20Gastric%20Cancer&rft.jtitle=Clinical%20cancer%20research&rft.au=Yao,%20James%20C&rft.date=2004-06-15&rft.volume=10&rft.issue=12&rft.spage=4109&rft.epage=4117&rft.pages=4109-4117&rft.issn=1078-0432&rft.eissn=1557-3265&rft_id=info:doi/10.1158/1078-0432.CCR-03-0628&rft_dat=%3Cproquest_cross%3E66652062%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=66652062&rft_id=info:pmid/15217947&rfr_iscdi=true |